-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
AT-130
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/211364-06-6.gif)
| Category | Hepatitis B Virus (HBV) |
| CAS | 211364-06-6 |
| Description | AT-130, a phenylpropenamide derivative, is a potent hepatitis B virus (HBV) replication non-nucleoside inhibitor. AT-130 inhibits the viral DNA synthesis with an EC50 of 0.13 μM. AT-130 inhibits both wt and mutant HBVs. AT-130 has anti-HBV activity in hepatoma cells. |
Product Information
| Synonyms | AT-130|211364-06-6|(E)-N-(1-bromo-1-(2-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-yl)-4-nitrobenzamide|N-[(1e)-1-Bromo-1-(2-Methoxyphenyl)-3-Oxo-3-(Piperidin-1-Yl)prop-1-En-2-Yl]-4-Nitrobenzamide|at130|CHEMBL316306|SCHEMBL5896791|SCHEMBL5896804|EX-A5164|N-[(E)-1-bromo-1-(2-methoxyphenyl)-3-oxo-3-piperidin-1-ylprop-1-en-2-yl]-4-nitrobenzamide|HY-100028|CS-0017999|N-[(E)-2-Bromo-2-(2-methoxyphenyl)-1-(piperidine-1-carbonyl)vinyl]-4-nitro-benzamide|N-[(E)-alpha-(Piperidinocarbonyl)-beta-bromo-2-methoxystyryl]-4-nitrobenzamide|N-{1-[Bromo(2-methoxyphenyl)methylene]-2-oxo-2-piperidylethyl}(4-nitrophenyl)carboxamide|(E)?-?N-?(1-?bromo-?1-?(2-?methoxyphenyl)?-?3-?oxo-?3-?(piperidin-?1-?yl)?prop-?1-?en-?2-?yl)?-?4-?nitrobenzamide |
| Molecular Weight | 488.33 |
| Molecular Formula | C22H22BrN3O5 |
| Canonical SMILES | COC1=CC=CC=C1C(=C(C(=O)N2CCCCC2)NC(=O)C3=CC=C(C=C3)[N+](=O)[O-])Br |
| Purity | 98.31% |
| Solubility | In Vitro: DMSO : 25 mg/mL(51.19 mM;Need ultrasonic) In Vivo: 1.Add each solvent one by one:10% DMSO >> 90%corn oil Solubility: ≥ 2.5 mg/mL (5.12 mM); Clear solution |
| Appearance | White to off-white (Solid) |
| Storage | Powder: -20°C 3 years In solvent: -80°C 6 months -20°C 1 months |
| Complexity | 694 |
| Exact Mass | 487.07428 |
| In Vitro | AT-130 inhibits Wt HBV (IC50=2.4 μM), rtL180M HBV (IC50=9.8 μM), rtM204I HBV (IC50=35.6 μM) AT-130 causes dose-dependent inhibition of wt HBV replication in HepG2 cells transduced with HBV baculovirus. AT-130 at a concentration of 2.5 μM, reduces encapsidated HBV DNA by 50% (IC50) and at 18.5 μM by 90% (IC90) AT-130 has no toxic to either HepG2 or Huh-7 cells at concentrations of up to 250 μM AT-130 does not inhibit HBV DNA synthesis by blocking the HBV endogenous DNA polymerase reaction directly in Huh 7 or HepG2 cells. AT-130 inhibits HBV DNA replication in hepatoma cells but has no effect on viral DNA polymerase activity or core protein translation. AT-130 has no effect on total HBV RNA production but does reduce encapsidated RNA. AT-130 does not affect core protein or nucleocapsid production and the activity of the protein expression vector. |
| Target | HBV; DNA/RNA Synthesis |
| XLogP3-AA | 4 |